Nanobiotix Reports Nanoprimer Breakthrough at AACR 2026
PARIS, France & CAMBRIDGE, USA, April 20, 2026 Nanobiotix has unveiled promising preclinical data demonstrating that its Nanoprimer technology...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
PARIS, France & CAMBRIDGE, USA, April 20, 2026 Nanobiotix has unveiled promising preclinical data demonstrating that its Nanoprimer technology...
TORONTO, ON, April 16, 2026 PharmaTher Holdings Ltd. has announced its strong support for proposed U.S. regulatory reclassification of...
PETACH TIKVA, Israel, April 16, 2026 Interna Therapeutics has announced a strategic research collaboration with Daiichi Sankyo to advance...
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...
DENVER, USA – March 18, 2026 TriSalus Life Sciences has announced new preclinical findings demonstrating that its Pressure-Enabled Drug...
Tacares de Grecia, Alajuela, Costa Rica – December 9, 2025 – Forj Medical, the newly formed CDMO created by...
September 18, 2025 — Cambridge, Massachusetts Biogen has announced the acquisition of Alcyone Therapeutics, a Massachusetts-based biotech company specializing...
